Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Tying Medical Organization Recommendations to Insurance Coverage
October 11, 2016 – AJMC Staff
ACA One of Many Points of Contention During Second Clinton-Trump Debate
October 10, 2016 – Christina Mattina
What We're Reading: Anthem Will Not Cover First Drug Approved for Duchenne
October 10, 2016 – AJMC Staff
Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC
October 10, 2016 – Surabhi Dangi-Garimella, PhD
Jakafi Named Recommended Treatment for Myelofibrosis in NCCN Guideline
October 09, 2016 – Laura Joszt
Most Americans Support Price Controls for Prescription Drug Costs, Poll Finds
October 09, 2016 – Jackie Syrop
Payment Tied to Patient Experience Improvement Benefits Hospitals Serving Minority Patients
October 08, 2016 – Jackie Syrop
Insured Patients Paying Substantial Out-of-Pocket Costs for Inpatient Care
October 08, 2016 – Jackie Syrop
5 Key Takeaways From AMCP Nexus 2016
October 07, 2016 – Laura Joszt

What We're Reading: Tying Medical Organization Recommendations to Insurance Coverage

AJMC Staff
What we're reading, October 11, 2016: USPSTF recommendations maybe shouldn't be tied to insurance coverage; growing dispute over homeopathy research; and the harm of pharmaceutical companies' copay assistant programs.
Task force recommendations for preventive services shouldn’t be tied to insurance coverage, experts are arguing. According to NPR, with the implementation of the Affordable Care Act, recommendations from the United States Preventive Services Task Force are tied to insurance coverage as insurers have to cover the costs. However, former members of the task force believe the system in place leaves it vulnerable to lobbying that can corrupt the process. For example, Mylan has been lobbying to have the EpiPen deemed a preventive service, which would make price increases invisible to patients, but not to insurers.

When has something been studied long enough? Two researchers are disagreeing about whether homeopathy, a controversial arm of complementary medicine, should continue to be studied despite studies already showing it doesn’t work, according to STAT. The part of the National Institutes of Health charged with researching alternative medicine is also skeptical about homeopathy. However, Americans spent $3 billion on homeopathic remedies in 2007 and the FDA allows them to be sold without requiring proof the products can meet their claims. Now critics are saying regulatory agencies should go further.

Pharmaceutical companies’ copay assistance programs for expensive drugs may seem helpful, but Peter A. Ubel, MD, and Peter B. Bach, MD, wrote about the consequences in an article in the Annals of Internal Medicine. Unfortunately, copay assistance programs reduce public outcry over price hikes because they diminish price pressures. Plus, as an artificial price support, patients have less incentive to act consumer savvy. One solution to the problem could be requiring that pharmaceutical companies offer copay assistance to all patients and for all products.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up